Technical Analysis for RGLS - Regulus Therapeutics Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Down | Down |
Historical RGLS trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Pocket Pivot | Bullish Swing Setup | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Bullish Engulfing | Bullish | 2.94% | |
Stochastic Buy Signal | Bullish | 2.94% | |
Pocket Pivot | Bullish Swing Setup | 2.94% | |
Lower Bollinger Band Walk | Weakness | 2.94% | |
Outside Day | Range Expansion | 2.94% | |
Wide Bands | Range Expansion | 2.94% | |
Lower Bollinger Band Touch | Weakness | 2.94% | |
Oversold Stochastic | Weakness | 2.94% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time |
---|---|
Rose Above 10 DMA | about 12 hours ago |
Rose Above Previous Day's High | about 12 hours ago |
10 DMA Resistance | about 12 hours ago |
Up 5% | about 12 hours ago |
Up 3% | about 12 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/12/2021
Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs to treat various diseases in the United States. The company utilizes its microRNA product platform to develop anti-miRs, a chemically modified single-stranded oligonucleotides. Its microRNA development candidates target miR-122 in hepatitis C virus infection; miR-21 and miR-221 in hepatocellular carcinoma; miR-21 in kidney fibrosis; miR-33 in atherosclerosis; and miR-10b in glioblastoma. The company has strategic alliances with AstraZeneca AB, GlaxoSmithKline plc, Sanofi, and Alnylam and Isis, as well as a strategic collaboration with Biogen Idec MA Inc. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Diseases Genetics Blastoma Carcinoma Glioblastoma Hepatitis C Glaxosmithkline Oligonucleotide Hepatitis C Virus Regulus Therapeutics Hepatocellular Carcinoma RNA Nucleic Acids Alnylam Pharmaceuticals Nucleotides Hepatitis C Virus Infection Atherosclerosis Microrna
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Diseases Genetics Blastoma Carcinoma Glioblastoma Hepatitis C Glaxosmithkline Oligonucleotide Hepatitis C Virus Regulus Therapeutics Hepatocellular Carcinoma RNA Nucleic Acids Alnylam Pharmaceuticals Nucleotides Hepatitis C Virus Infection Atherosclerosis Microrna
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 2.32 |
52 Week Low | 0.4222 |
Average Volume | 3,517,007 |
200-Day Moving Average | 0.97 |
50-Day Moving Average | 1.55 |
20-Day Moving Average | 1.52 |
10-Day Moving Average | 1.42 |
Average True Range | 0.18 |
ADX | 17.44 |
+DI | 15.77 |
-DI | 20.99 |
Chandelier Exit (Long, 3 ATRs ) | 1.35 |
Chandelier Exit (Short, 3 ATRs ) | 1.70 |
Upper Bollinger Band | 1.83 |
Lower Bollinger Band | 1.21 |
Percent B (%b) | 0.31 |
BandWidth | 40.96 |
MACD Line | -0.06 |
MACD Signal Line | -0.03 |
MACD Histogram | -0.0257 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 1.76 | ||||
Resistance 3 (R3) | 1.74 | 1.61 | 1.70 | ||
Resistance 2 (R2) | 1.61 | 1.51 | 1.62 | 1.68 | |
Resistance 1 (R1) | 1.50 | 1.46 | 1.56 | 1.52 | 1.66 |
Pivot Point | 1.37 | 1.37 | 1.39 | 1.38 | 1.37 |
Support 1 (S1) | 1.26 | 1.27 | 1.32 | 1.28 | 1.14 |
Support 2 (S2) | 1.13 | 1.22 | 1.14 | 1.12 | |
Support 3 (S3) | 1.02 | 1.13 | 1.10 | ||
Support 4 (S4) | 1.04 |